• Home
  •  / NovaBay Pharmaceuticals

NovaBay Pharmaceuticals

OverviewSuggest Edit

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company developing products for the eye care market. We are currently focused primarily on commercializing prescription Avenova® for managing hygiene of the eyelids and lashes in the United States.

Avenova is the only eye care product formulated with a proprietary, stable and pure form of hypochlorous acid called Neutrox®. By replicating the anti-microbial chemicals used by white blood cells to fight infection, Neutrox has proven in laboratory testing to have broad antimicrobial properties. Avenova with Neutrox removes debris from the skin on eyelids and lashes without burning or stinging.

We have developed additional commercial products containing Neutrox, including our NeutroPhase® Skin and Wound Cleanser for wound care and CelleRx® for the dermatology market. We have partnerships for NeutroPhase in the U.S. as well as select overseas markets, most notably China.

TypePublic
Founded2000
HQEmeryville, CA, USMap
Websitenovabay.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2019)33(-52%)
Revenue (FY, 2019)$6.6 M(-47%)
Share Price (Jan 2021)$0.8 (+2%)
Cybersecurity ratingAMore

Key People/Management at NovaBay Pharmaceuticals

Paul E. Freiman

Paul E. Freiman

Chairman of the Board of Directors
Justin Hall

Justin Hall

Chief Executive Officer
Andrew Jones

Andrew Jones

Chief Financial Officer
Show more

NovaBay Pharmaceuticals Office Locations

NovaBay Pharmaceuticals has an office in Emeryville
Emeryville, CA, US (HQ)
2000 Powell St #1150
Show all (1)

NovaBay Pharmaceuticals Financials and Metrics

NovaBay Pharmaceuticals Revenue

NovaBay Pharmaceuticals's revenue was reported to be $6.60 m in FY, 2019
USD

Revenue (Q2, 2020)

4.0m

Gross profit (Q2, 2020)

1.9m

Gross profit margin (Q2, 2020), %

48.8%

Net income (Q2, 2020)

(4.5m)

EBIT (Q2, 2020)

(1.1m)

Market capitalization (8-Jan-2021)

32.3m

Closing stock price (8-Jan-2021)

0.8

Cash (30-Jun-2020)

8.8m

EV

25.0m
NovaBay Pharmaceuticals's current market capitalization is $32.3 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

11.0m6.9m3.3m370.0k4.4m11.9m18.2m12.5m6.6m

Cost of goods sold

162.0k486.0k1.3m2.5m2.8m1.5m1.7m

Gross profit

3.1m(116.0k)3.1m9.4m15.4m11.0m4.9m

Gross profit Margin, %

95%(31%)71%79%85%88%74%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

4.5m2.8m1.3m871.0k3.6m957.0k831.0k1.1m100.0k102.0k62.0k46.0k1.0m1.2m1.7m2.7m3.4m3.7m4.1m4.1m2.9m2.8m3.1m1.5m1.8m1.6m1.9m4.0m

Cost of goods sold

22.0k16.0k43.0k130.0k18.0k42.0k148.0k253.0k269.0k479.0k566.0k588.0k698.0k521.0k251.0k479.0k332.0k341.0k403.0k401.0k581.0k2.0m

Gross profit

935.0k815.0k1.1m(30.0k)84.0k20.0k(102.0k)755.0k931.0k2.2m2.9m3.1m3.4m3.6m2.7m2.3m2.8m1.2m1.4m1.2m1.3m1.9m

Gross profit Margin, %

98%98%96%(30%)82%32%(222%)75%78%82%84%84%83%87%91%83%89%77%77%75%69%49%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

8.4m12.7m10.5m5.4m2.4m9.5m3.2m3.2m6.9m

Accounts Receivable

3.0k943.0k784.0k273.0k536.0k113.1m3.6m3.4m1.1m

Prepaid Expenses

417.0k445.0k723.0k729.0k261.0k1.7m1.8m886.0k

Inventories

23.0k231.0k521.0k1.3m2.0m504.0k280.0k492.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

8.0m12.4m6.1m4.7m7.2m8.4m6.6m6.9m10.3m7.8m7.9m5.6m7.2m3.4m1.4m3.5m9.4m7.4m5.7m6.1m8.3m6.8m5.2m2.9m3.7m9.0m5.7m8.8m

Accounts Receivable

3.6m1.8m1.0m9.0k126.0k916.0k112.0k272.0k260.0k440.0k364.0k283.0k389.0k543.0k1.5m2.1m2.3m3.6m2.2m2.2m2.0m2.6m2.4m1.5m1.5m952.0k1.4m

Prepaid Expenses

586.0k289.0k427.0k506.0k508.0k365.0k427.0k330.0k794.0k656.0k514.0k1.2m597.0k668.0k474.0k1.8m1.0m972.0k1.0m1.8m1.6m1.3m1.5m1.6m1.1m662.0k1.1m

Inventories

61.0k48.0k63.0k155.0k218.0k405.0k492.0k1.5m1.6m1.2m1.1m1.1m765.0k672.0k599.0k479.0k317.0k390.0k302.0k664.0k838.0k552.0k626.0k
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(5.1m)(7.0m)(16.0m)(15.2m)(19.0m)(13.2m)(7.4m)(6.5m)(9.7m)

Depreciation and Amortization

425.0k341.0k314.0k232.0k164.0k114.0k95.0k266.0k65.0k

Inventories

(23.0k)(208.0k)(451.0k)(751.0k)472.0k369.0k198.0k(212.0k)

Accounts Payable

345.0k665.0k1.4m(252.0k)1.7m(2.2m)(260.0k)516.0k(1.8m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(1.6m)(1.5m)(2.5m)(4.8m)(4.7m)(4.0m)(8.1m)(11.9m)(3.6m)(6.5m)(10.7m)(4.6m)(9.5m)(14.8m)(5.1m)(7.8m)(11.5m)(4.0m)(5.7m)(8.2m)(2.1m)(3.7m)(5.3m)(4.2m)(6.7m)(7.0m)(1.6m)(6.1m)

Depreciation and Amortization

216.0k321.0k91.0k174.0k256.0k81.0k161.0k240.0k70.0k141.0k185.0k41.0k82.0k123.0k40.0k67.0k98.0k18.0k36.0k54.0k41.0k127.0k219.0k17.0k33.0k50.0k14.0k28.0k

Inventories

(38.0k)(25.0k)(40.0k)76.0k12.0k(175.0k)29.0k(871.0k)(1.0m)144.0k193.0k261.0k108.0k200.0k273.0k160.0k89.0k(21.0k)(383.0k)(558.0k)(59.0k)(134.0k)

Accounts Payable

287.0k(167.0k)167.0k785.0k1.3m(222.0k)400.0k959.0k(1.2m)(1.4m)(1.1m)357.0k(286.0k)1.1m(1.7m)(2.1m)234.0k390.0k602.0k(161.0k)(327.0k)(56.0k)(521.0k)(1.4m)(1.6m)(175.0k)473.0k
show all
USDQ2, 2011

Financial Leverage

1.6 x
Show all financial metrics

NovaBay Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

Learn more about our premium products
SecurityScorecard logo

NovaBay Pharmaceuticals Online and Social Media Presence

NovaBay Pharmaceuticals's Trends

Embed Graph

NovaBay Pharmaceuticals News and Updates

December 01, 2020

$ 2,153.51 Mn Wound Irrigation Solutions Market share in 2020 to 2027 | Schülke & Mayr, NovaBay Pharmaceuticals, Reckitt Benckiser Group

The global wound irrigation solutions market expected to be US$ 1,580.14 Mn in 2018 and is predicted to grow at a CAGR of 3.5% during the forecast period 2019 – 2027, to reach US$ 2,153.51 Mn by 2027. Posted via Industry Today. Follow us on Twitter @IndustryToday
October 02, 2020

Thinking about buying stock in Lonestar Resources, Nikola Corp, Cassava Sciences, NovaBay Pharmaceuticals, or Zoom Video?

NEW YORK, Oct. 2, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LONE, NKLA, SAVA, NBY, and ZM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
August 18, 2020

Thinking about buying stock in NovaBay Pharmaceuticals, RISE Education, eMagin Corp, Avinger Inc, or Clovis Oncology?

NEW YORK, Aug. 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NBY, REDU, EMAN, AVGR, and CLVS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
July 13, 2020

Thinking about buying stock in electroCore, NovaBay Pharmaceuticals, Dolphin Entertainment, Vuzix Corp, or Spirit Airlines?

NEW YORK, July 13, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ECOR, NBY, DLPN, VUZI, and SAVE. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
August 09, 2019

NovaBay Pharmaceuticals Announces Pricing of $2.7 Million Private Placement of Preferred Stock and Accompanying Warrants to Purchase Common Stock

EMERYVILLE, Calif., Aug. 09, 2019 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care market, today announced that it has entered into a securities purchase agreement with certain non-U.S…
August 09, 2019

NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered Direct Offering

EMERYVILLE, Calif., Aug. 09, 2019 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care market, today announced that it has entered into a securities purchase agreement with certain institu…
Show more

 NovaBay Pharmaceuticals Frequently Asked Questions

  • When was NovaBay Pharmaceuticals founded?

    NovaBay Pharmaceuticals was founded in 2000.

  • Who are NovaBay Pharmaceuticals key executives?

    NovaBay Pharmaceuticals's key executives are Paul E. Freiman, Justin Hall and Andrew Jones.

  • How many employees does NovaBay Pharmaceuticals have?

    NovaBay Pharmaceuticals has 33 employees.

  • What is NovaBay Pharmaceuticals revenue?

    Latest NovaBay Pharmaceuticals annual revenue is $6.6 m.

  • What is NovaBay Pharmaceuticals revenue per employee?

    Latest NovaBay Pharmaceuticals revenue per employee is $200 k.

  • Who are NovaBay Pharmaceuticals competitors?

    Competitors of NovaBay Pharmaceuticals include Bird Rock Bio, SmartZyme and Patheon.

  • Where is NovaBay Pharmaceuticals headquarters?

    NovaBay Pharmaceuticals headquarters is located at 2000 Powell St #1150, Emeryville.

  • Where are NovaBay Pharmaceuticals offices?

    NovaBay Pharmaceuticals has an office in Emeryville.

  • How many offices does NovaBay Pharmaceuticals have?

    NovaBay Pharmaceuticals has 1 office.